Skip to content

Full Event Guide

Download the Neuromuscular Drug Development Agenda

What’s new at NMD this year:

  1. Workshop on effectively using biomarkers within clinical trials to enrich the patient selection, provide evidence of target engagement and understand which mechanisms reflect an effect and identify responders - Susan Ward, Head of Clinical Operations, Brainstorm Cell Therapeutics

  2. Kirsten Gruis, Global Head, Neuromuscular, Roche will be evaluating if there is still a role for small molecule treatments for neuromuscular disorders
    t
  3. Assessing the current neuromuscular clinical landscape with Biogen - Nicolas Currier, Associate Medical Director and Satish Eraly, Medical Director
    t
  4. Panel discussion to assess current approval considerations and current regulation – what needs to change? Ralph Kern, Chief Medical Officer, Brainstorm Cell Therapeutics & Jane Larkindale, Executive Director, Critical Path Institute
    t
  5. Discussing the limitations of preclinical models with Rajasekhar Suragani, Director of Preclinical & Translational Exploratory Biology, Acceleron Pharma
    t
  6. 7+ hours of dedicated networking time enabling you to form connections for future partnerships
    t
  7. Establish your work in the field and share your research with your peers at the Poster Session